Astex Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Astex Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#448 of 15,742 sponsors by registered trial count).
Astex Pharmaceuticals: 38 sponsored US clinical trials, none currently recruiting.
Astex Pharmaceuticals sponsors 38 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 29 completed. 5 of these trials are in Phase 3-4 (later-stage) and 32 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Myelogenous Leukemia, with 1 trials.
Top-decile sponsor footprint
Astex Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#448 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
29 of 38 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
38 total, page 1 of 1
A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
NCT05835011
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
NCT04637009
A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029
NCT04466514
Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers
NCT04479800
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT04155580
A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
NCT04411030
Effect of Food on Blood Levels of ASTX727
NCT03813186
Guadecitabine Extension Study
NCT03603964
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
NCT03306264
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
NCT02920008
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
NCT02907359
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
NCT02348489
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
NCT02103478
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
NCT01752933
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
NCT01712217
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
NCT01685268
SGI-110 in Combination With Carboplatin in Ovarian Cancer
NCT01696032
A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
NCT01357395
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
NCT01294202
SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
NCT01261312
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
NCT01183949
Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
NCT00848601
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
NCT00878423
Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors
NCT00881166
Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies
NCT00894894
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
NCT00504205
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
NCT00522990
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
NCT00113256
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT00041990
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT00042003
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT00042016
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
NCT00032773
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
NCT00113113
Decitabine Versus Supportive Care in Adults With Advanced-stage MDS
NCT00043381
Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
NCT00005873
Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
NCT00005874
Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer
NCT00005872
Nitrocamptothecin in Treating Patients With Metastatic Melanoma
NCT00005875
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 14 |
| Phase 3 | 5 |
Therapeutic Areas
How the Astex Pharmaceuticals early-phase archive is shaped
38 indexed studies, none listed as recruiting (0% open); 29 completed (76%).
Phase mix: 5 late (III/IV) vs 32 early (I/II) (early-phase heavy).
Top condition: Chronic Myelogenous Leukemia (1 trial), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Astex Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 38 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Astex Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 38 archived trials
- Acerta Pharma · 38 trials · 0% recruiting
- Corewell Health West · 38 trials · 11% recruiting
- DePuy Orthopaedics · 38 trials · 5% recruiting
- Ethicon · 38 trials · 11% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Astex Pharmaceuticals page
38 registered trials is a research-attention snapshot, not an endorsement of Astex Pharmaceuticals or any single study.
- None of Astex Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Chronic Myelogenous Leukemia is the condition Astex Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Myelogenous Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Astex Pharmaceuticals pipeline card: 38 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.